GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SanBio Co Ltd (TSE:4592) » Definitions » EV-to-FCF

SanBio Co (TSE:4592) EV-to-FCF : (As of May. 22, 2024)


View and export this data going back to 2015. Start your Free Trial

What is SanBio Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, SanBio Co's Enterprise Value is 円27,436.81 Mil. SanBio Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2024 was 円0.00 Mil. Therefore, SanBio Co's EV-to-FCF for today is .

The historical rank and industry rank for SanBio Co's EV-to-FCF or its related term are showing as below:

TSE:4592' s EV-to-FCF Range Over the Past 10 Years
Min: -11.16   Med: 0   Max: 0
Current: -5.78

TSE:4592's EV-to-FCF is ranked worse than
100% of 376 companies
in the Biotechnology industry
Industry Median: 9.49 vs TSE:4592: -5.78

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-22), SanBio Co's stock price is 円455.00. SanBio Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was 円-40.538. Therefore, SanBio Co's PE Ratio for today is At Loss.


SanBio Co EV-to-FCF Historical Data

The historical data trend for SanBio Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SanBio Co EV-to-FCF Chart

SanBio Co Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.70 -14.25 -8.19 -5.63 -7.19

SanBio Co Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.63 - - - -7.19

Competitive Comparison of SanBio Co's EV-to-FCF

For the Biotechnology subindustry, SanBio Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SanBio Co's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SanBio Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where SanBio Co's EV-to-FCF falls into.



SanBio Co EV-to-FCF Calculation

SanBio Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=27436.808/0
=

SanBio Co's current Enterprise Value is 円27,436.81 Mil.
SanBio Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SanBio Co  (TSE:4592) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

SanBio Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=455.00/-40.538
=At Loss

SanBio Co's share price for today is 円455.00.
SanBio Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-40.538.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


SanBio Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of SanBio Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


SanBio Co (TSE:4592) Business Description

Traded in Other Exchanges
Address
8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku, Tokyo, JPN, 104-0044
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.

SanBio Co (TSE:4592) Headlines

No Headlines